Citations

Clear

4 citation(s) found for "Schofer, Joachim".

TRI-SCORE and benefit of intervention in patients with severe tricuspid regurgitation
Dreyfus, Julien , Galloo, Xavier , Heitzinger, Gregor , Benfari, Giovanni , Kresoja, Karl-Patrick, Juarez-Casso, Fernando M. , Omran, Hazem , Russo, Giulio , Topilsky, Yan , Weber, Marcel, Sala, Alessandra , Eixerés‐Esteve, Andrea , Riant, Elisabeth , Donal, Erwan , Hausleiter, Jörg , Badano, Luigi P. , Coisne, Augustin , Windecker, Stephan , Zamorano, José Luis , Tang, Gilbert H L, Webb, John G. , Muraru, Denisa , Nejjari, Mohammed , Bonis, Michele De , Carnero, Manuel , Nickenig, Georg, Pfister, Roman , Tribouilloy, Christophe , Rudolph, Volker , Lurz, Philipp , Bartko, Philipp E. , Messika–Zeitoun, David , investigators, TRIGISTRY, Heitzinger, Gregor, Bohbot, Yohan, Topilsky, Yan , Weber, Marcel, Lim, Pascal , Bazire, Baptiste , Donal, Erwan, Tourneau, Thierry Le, Modine, Thomas, Doguet, Fabien , Ajmone-Marsan, N, Stolz, Lukas, Praz, Fabien, Zamorano, José Luís , Bardeleben, Ralph Stephan von, Tang, Gilbert H L, Lubos, Edith, Webb, John A., Schöfer, Joachim, Fam, Neil , Lauten, Alexander , Pedrazzini, Giovanni , Rodés‐Cabau, Josep , Gavazzoni, Mara , Flagiello, Michele, Radu, Costin , Mbaki, Yannick, Tomasi, Jacques , Sénage, Thomas , Chan, Vincent, Alessandrini, Hannes , Eyharts, Damien , Viau, F , Himbert, Dominique , Sievert, Horst, Eggenspieler, Florian , Nicol, Martin , Nickenig, Georg , Pfister, Romain, Crestanello, Juan, Maisano, Francesco, Messika-Zeitoun, David, Kresoja, Karl-Patrik , Heitzinger, Gregor , Juarez-Casso, Fernando, Omran, Hazem , Russo, Giulio , Topilsky, Yan , Nombela-Franco, Luis , Riant, Elisabeth , Donal, Erwan , Hausleiter, Jörg , Coisne, Augustin , Praz, Fabien , Windecker, Stephan , Nejjari, Mohammed , Chan, Vincent , De Bonis, Michele , Carnero-Alcazar, Manuel , Pfister, Roman , Tribouilloy, Christophe , Rudolph, Volker , Lurz, Philipp , Maisano, Francesco , Messika-Zeitoun, David , Enriquez-Sarano, Maurice , Benfari, Giovanni , Kresoja, Karl-Patrik , Taramasso, Maurizio , Bohbot, Yohann , Iliadis, Christos , Weber, Marcel , Nombela‐Franco, Luis , Iung, Bernard , Obadia, Jean‐François , Estévez‐Loureiro, Rodrigo , Tourneau, Thierry Le , Modine, Thomas , Latib, Azeem , Praz, Fabien , von Bardeleben, Ralph Stephan , Tang, Gilbert H L, Hahn, Rebecca T , Chan, Vincent , Crestanello, Juan A. , Maisano, Francesco , Bax, Jeroen J. , Enriquez‐Sarano, Maurice , investigators, TRIGISTRY, Heitzinger, Gregor, Weber, Marcel, Donal, Erwan, Tourneau, Thierry Le, Modine, Thomas, Lavie-Badie, Yoan , Habib, Gilbert , Selton‐Suty, Christine , Stolz, Lukas , Praz, Fabien, Bardeleben, Ralph Stephan von, Ruf, Tobias Friedrich , Tang, Gilbert H L, Webb, John, Michelena, Héctor I. , Solı́s, Jorge , Flagiello, Michele, Chan, Vincent, Rahmouni, Kenza , Viau, Florence, Pfister, R, Crestanello, Juan, Maisano, Francesco, Messika-Zeitoun, David

Mayo Clinic

European Heart Journal | August 24, 2023 | Volume: 45 | Issue: 8 | Pages: 586-597

10.1093/eurheartj/ehad585 | PMID 37624856 Get It

Abstract Background and aims Benefit of tricuspid regurgitation (TR) correction and timing of intervention are unclear. This study aimed to compare survival rates after surgical or transcatheter intervention to conservative management according to a TR clinical stage as assessed using the TRI-SCORE. Methods A total of 2,413 patients with severe isolated functional TR were enrolled in TRIGISTRY (1217 conservatively managed, 551 isolated tricuspid valve surgery, and 645 transcatheter valve repair). The primary endpoint was survival at 2 years. Results The TRI-SCORE was low (≤3) in 32%, intermediate (4–5) in 33%, and high (≥6) in 35%. A successful correction was achieved in 97% and 65% of patients in the surgical and transcatheter groups, respectively. Survival rates decreased with the TRI-SCORE in the three treatment groups (all P < .0001). In the low TRI-SCORE category, survival rates were higher in the surgical and transcatheter groups than in the conservative management group (93%, 87%, and 79%, respectively, P = .0002). In the intermediate category, no significant difference between groups was observed overall (80%, 71%, and 71%, respectively, P = .13) but benefit of the intervention became significant when the analysis was restricted to patients with successful correction (80%, 81%, and 71%, respectively, P = .009). In the high TRI-SCORE category, survival was not different to conservative management in the surgical and successful repair group (61% and 68% vs 58%, P = .26 and P = .18 respectively). Conclusions Survival progressively decreased with the TRI-SCORE irrespective of treatment modality. Compared to conservative management, an early and successful surgical or transcatheter intervention improved 2-year survival in patients at low and, to a lower extent, intermediate TRI-SCORE, while no benefit was observed in the high TRI-SCORE category.
Transcatheter Mitral Valve Replacement After Surgical Repair or Replacement
Simonato, Matheus , Ribeiro, Henrique Barbosa , Webb, John G. , Backer, Ole De , Villablanca, Pedro, Rihal, Charanjit S. , Eleid, Mackram F. , Kempfert, Jörg , Unbehaun, Axel , Erlebach, Magdalena , Casselman, Filip , Saia, Francesco , Ubben, Timm , Meincke, Felix , Napodano, Massimo, Codner, Pablo , Schöfer, Joachim, Pelletier, Marc , Cheung, Anson , Shuvy, Mony , Palma, José Honório , Duncan, Alison , Sinning, Jan-Malte, Arbel, Yaron , Weger, Arend de , Eltchaninoff, Hélène, Hemery, Thibault, Tchétché, Didier , Dumonteil, Nicolas, Rodés‐Cabau, Josep , Kim, Won-Keun, Spargias, Konstantinos, Kourkoveli, Panagiota, Ben‐Yehuda, Ori , Barbanti, Marco , Fiorina, Claudia , Thukkani, Arun K., Jones, Noah, Presbitero, Patrizia , Petronio, Anna Sonia , Champagnac, Didier , Rudolph, Tanja K. , Iadanza, Alessandro , Nombela‐Franco, Luis , Bonaros, Nikolaos , Kass, Malek , Amabile, Nicolas , Messina, Antonio , Andreas, Martin , Welsh, Robert C. , Schoels, Wolfgang , Hellig, Farrel, Windecker, Stephan , Stortecky, Stefan , Maisano, Francesco , Stone, Gregg W. , Dvir, Danny , Rihal, Charanjit, Eleid, Mackram, Nombela-Franco, Luis , Windecker, Stephan , Maisano, Francesco , De Backer, Ole , Whisenant, Brian K. , Kornowski, Ran , Guerrero, Mayra , Wijeysundera, Harindra C. , Søndergaard, Lars , Rihal, Charanjit S. , Adam, Matti , Montorfano, Matteo , Ancona, Marco , Gaia, Diego Felipe , Hildick-Smith, David , Veulemans, Verena , Sinning, Jan‐Malte, Testa, Luca , Landes, Uri , Kim, Won-Keun, Teles, Rui Campante , Mackensen, G. Burkhard , Allali, Abdelhakim , Bleiziffer, Sabine , Salizzoni, Stefano , Agrifoglio, Marco , Bruschi, Giuseppe , Chhatriwalla, Adnan K , Hirji, Sameer

Mayo Clinic

Circulation | September 25, 2020 | Volume: 143 | Issue: 2 | Pages: 104-116

10.1161/circulationaha.120.049088 | PMID 32975133 Get It

Background: Mitral valve-in-valve (ViV) and valve-in-ring (ViR) are alternatives to surgical reoperation in patients with recurrent mitral valve failure after previous surgical valve repair or replacement. Our aim was to perform a large-scale analysis examining midterm outcomes after mitral ViV and ViR. Methods: Patients undergoing mitral ViV and ViR were enrolled in the Valve-in-Valve International Data Registry. Cases were performed between March 2006 and March 2020. Clinical endpoints are reported according to the Mitral Valve Academic Research Consortium (MVARC) definitions. Significant residual mitral stenosis (MS) was defined as mean gradient ≥10 mm Hg and significant residual mitral regurgitation (MR) as ≥ moderate. Results: A total of 1079 patients (857 ViV, 222 ViR; mean age 73.5±12.5 years; 40.8% male) from 90 centers were included. Median STS-PROM score 8.6%; median clinical follow-up 492 days (interquartile range, 76–996); median echocardiographic follow-up for patients that survived 1 year was 772.5 days (interquartile range, 510–1211.75). Four-year Kaplan-Meier survival rate was 62.5% in ViV versus 49.5% for ViR ( P <0.001). Mean gradient across the mitral valve postprocedure was 5.7±2.8 mm Hg (≥5 mm Hg; 61.4% of patients). Significant residual MS occurred in 8.2% of the ViV and 12.0% of the ViR patients ( P =0.09). Significant residual MR was more common in ViR patients (16.6% versus 3.1%; P <0.001) and was associated with lower survival at 4 years (35.1% versus 61.6%; P =0.02). The rates of Mitral Valve Academic Research Consortium–defined device success were low for both procedures (39.4% total; 32.0% ViR versus 41.3% ViV; P =0.01), mostly related to having postprocedural mean gradient ≥5 mm Hg. Correlates for residual MS were smaller true internal diameter, younger age, and larger body mass index. The only correlate for residual MR was ViR. Significant residual MS (subhazard ratio, 4.67; 95% CI, 1.74–12.56; P =0.002) and significant residual MR (subhazard ratio, 7.88; 95% CI, 2.88–21.53; P <0.001) were both independently associated with repeat mitral valve replacement. Conclusions: Significant residual MS and/or MR were not infrequent after mitral ViV and ViR procedures and were both associated with a need for repeat valve replacement. Strategies to improve postprocedural hemodynamics in mitral ViV and ViR should be further explored.
Relationship of Late Loss in Lumen Diameter to Coronary Restenosis in Sirolimus-Eluting Stents
O’Malley, A. James , Moses, Jeffrey W. , Leon, Martin B. , Holmes, David R. , Teirstein, Paul S., Schofer, Joachim, Breithardt, Günter, Cutlip, Donald E. , Kereiakes, Dean J. , Shi, Chunxue , Firth, Brian G., Donohoe, Dennis, Kuntz, Richard E., Mauri, Laura , Orav, E. John

Mayo Clinic

Circulation | January 18, 2005 | Volume: 111 | Issue: 3 | Pages: 321-327

10.1161/01.cir.0000153356.72810.97 | PMID 15655127 Get It

Background— Observed rates of restenosis after drug-eluting stenting are low (<10%). Identification of a reliable and powerful angiographic end point will be useful in future trials. Methods and Results— Late loss (postprocedural minimum lumen diameter minus 8-month minimum lumen diameter) was measured in the angiographic cohorts of the SIRIUS (n=703) and E-SIRIUS (n=308) trials. Two techniques, the standard normal approximation and an optimized power transformation, were used to predict binary angiographic restenosis rates and compare them with observed restenosis rates. The mean in-stent late loss observed in the SIRIUS trial was 0.17±0.45 mm (sirolimus) versus 1.00±0.70 mm (control). If a normal distribution was assumed, late loss accurately estimated in-stent binary angiographic restenosis for the control arm (predicted 35.4% versus observed 35.4%) but underestimated it in the sirolimus arm (predicted 0.6% versus observed 3.2%). Power transformation improved the reliability of the estimate in the sirolimus arm (predicted 3.2% [CI 1.0% to 6.7%]) with similar improvements in the E-SIRIUS trial (predicted 4.0% [CI 1.2% to 7.0%] versus observed 3.9%). In the sirolimus-eluting stent arm, in-stent late loss correlated better with target-lesion revascularization than in-segment late loss (c-statistic=0.915 versus 0.665). Conclusions— Because distributions of late loss with a low mean are right-skewed, the use of a transformation improves the accuracy of predicting low binary restenosis rates. Late loss is monotonically correlated with the probability of restenosis and yields a more efficient estimate of the restenosis process in the era of lower binary restenosis rates.